Search

Search Results

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4490

  PDF: 1562

  HTML: 3741

• Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF

  Wen Yao, Xinchen Fang, Peng Jiang, Juan Tong, Liangquan Geng, Xiaoyu Zhu, Baolin Tang, Xiang Wan, Kaidi Song, Lei Zhang, Ping Qiang, Guangyu Sun, Yongsheng Han, Huilan Liu, Zimin Sun

  e2022025

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.025

  1908

  PDF: 647

  HTML: 370

• PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries

  Dr, Moleti, Anna Maria Testi

  e2024078

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.078

  1401

  PDF: 985

  HTML: 355

• BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.

  Roberto Castelli

  e2016030

  2016-07-01

  https://doi.org/10.4084/mjhid.2016.030

  6128

  PDF: 1043

  HTML: 2353

• ITPA POLYMORPHISMS AND THE INCIDENCE OF TOXICITIES IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  Patpetra Svasdisant, Waraporn Glomglao, Preeyanun Siraprapapat, Wiyakan Inthararujikul , Kalaya Tachavanich, Chetsada Boonthimat, Sakkarin Ardsiri, Kochpinchon Chansing, Suwimon Sriprach , Sasima Tongsai , Phakatip Sinlapamongkolkul , Kleebsabai Sanpakit , Jassada Buaboonnam

  e2023024

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.024

  1317

  PDF: 1048

  HTML: 406

• IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE

  Francesco Di Raimondo, Giorgio La Nasa

  e2014039

  2014-05-29

  https://doi.org/10.4084/mjhid.2014.039

  2333

  PDF: 1059

  HTML: 1993

• CLINICAL ANALYSIS AND OPTIMIZATION OF POST-REMISSION THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AS DETERMINED BY FLOW CYTOMETRY

  Daichi Inoue, Hayato Maruoka, Takayuki Takahashi

  e2010020

  2010-08-05

  https://doi.org/10.4084/mjhid.2010.020

  1393

  PDF: 800

  HTML: 1253

• OUTCOME AND TOXICITY PATTERNS IN CHILDREN AND ADOLESCENTS WITH NON-HODGKIN LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE

  Paola Angelini, Laura Rodriguez, Mohammed Zolaly, Ahmed Naqvi, Sheila Weitzman, oussama Abla, Angela Punnett

  e2018020

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.020

  3081

  PDF: 905

  HTML: 435

• PROGNOSTIC SIGNIFICANCE OF NRAS GENE MUTATIONS IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA

  Rabab Aly, Mohamed R. El-sharnoby, Adel A. Hagag

  e2011055

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.055

  1977

  PDF: 822

  HTML: 1587

• PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA

  Annarosa Cuccaro, Francesca Bartolomei, Elisa Cupelli, Stefan Hohaus

  e2014053

  2014-07-04

  https://doi.org/10.4084/mjhid.2014.053

  3529

  PDF: 2096

  HTML: 7585

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2290

  PDF: 821

  HTML: 1651

• FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA.

  Daniele Avenoso, Amal Alabdulwahab, Michelle Kenyon, Varun Mehra, Pramila Krishnamurthy, Francesco Dazzi, Ye Ting Leung, Sandra Anteh, Mili Naresh Shah, Andrea Kuhnl, Robin Sanderson, Piers Patten, Deborah Yallop, Antonio Pagliuca, Victoria Potter

  e2023041

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.041

  1738

  PDF: 798

  HTML: 252

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2626

  PDF: 862

  HTML: 1756

• DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA

  Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos

  e2019016

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.016

  2159

  PDF: 1200

  HTML: 334

• HEPATITIS C VIRUS INFECTION AND LYMPHOMA

  Emmanuel Bachy, Caroline Besson, Felipe Suarez, Olivier Hermine

  e2010004

  2010-03-25

  https://doi.org/10.4084/mjhid.2010.004

  1141

  PDF: 770

  HTML: 7884

• NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?

  Alessandro Corso, Silvia Mangiacavalli

  e2017053

  2017-08-18

  https://doi.org/10.4084/mjhid.2017.053

  3424

  PDF: 1791

  HTML: 1180

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4446

  PDF: 1611

  HTML: 482

• AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS

  Grzegorz Helbig, Malgorzata Krawczyk-Kulis, Malgorzata Kopera, Krystyna Jagoda, Patrycja Rzepka, Aleksandra Majewska-Tessar, Marta Hejla, Slawomira Kyrcz-Krzemien

  e2014047

  2014-06-29

  https://doi.org/10.4084/mjhid.2014.047

  1644

  PDF: 982

  HTML: 2015

  Figure: 220

  Tables: 231

  ALL revision 1: 331

  response to reviewer: 229

• EARLY PREDICTORS OF RENAL DYSFUNCTION IN ?-THALASSEMIA MAJOR AND INTERMEDIA PATIENTS

  Azza A.G. Tantawy, Nagham El Bablawy, Amira A. M Adly, Fatma S E Ebeid

  e2014057

  2004-09-01

  https://doi.org/10.4084/mjhid.2014.057

  2101

  PDF: 1029

  HTML: 3915

• INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?

  Francesco Zallio, Giulia Limberti, Marco Ladetto

  e2017035

  2017-05-01

  https://doi.org/10.4084/mjhid.2017.035

  3421

  PDF: 1110

  HTML: 2564

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1850

  PDF: 1396

  HTML: 670

• GASTROINTESTINAL MYELOID SARCOMA A CASE PRESENTATION AND CRITICAL REVIEW OF THE LITERATURE GASTROINTESTINAL MYELOID SARCOMA

  Pouyan Kheirkhah, Ana M. Avila-Rodriguez, Bartlomiej Radzik, Carlos Murga-Zamalloa

  e2021067

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.067

  1897

  PDF: 708

  HTML: 371

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1752

  PDF: 804

  HTML: 1515

• POEMS SYNDROME: AN UPDATE

  Andrea Nozza

  e2017051

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.051

  3532

  PDF: 1752

  HTML: 1808

• EBV IN HODGKIN LYMPHOMA

  Giuseppina Massini, Doerte Siemer, Stefan Hohaus

  e2009013

  https://doi.org/10.4084/mjhid.2009.013

  1778

  PDF: 663

  HTML: 14161

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  2122

  PDF: 1767

  HTML: 469

• CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY

  Lodovico Balducci

  e2014037

  2014-05-31

  https://doi.org/10.4084/mjhid.2014.037

  2997

  PDF: 1197

  HTML: 3086

• TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.

  Aditi Singh, MD, Ishaq Asghar, MD, Laura Kohler, DO, Hosam Hakim, MD, Daniel Snower, MD, Daniel Lebovic, MD

  e2022018

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.018

  2075

  PDF: 856

  HTML: 621

• GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

  Angela Stoddart, Megan E. McNerney, Elizabeth Bartom, Rachel Bergerson, David J. Young, Zhijian Qian, Jianghong Wang, Anthony A. Fernald, Elizabeth M. Davis, Richard A. Larson, Kevin P. White, Michelle M. Le Beau

  e2011019

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.019

  2715

  PDF: 877

  HTML: 5393

• ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  Mohamed L. Sorror, Rainer F. Storb

  e2010015

  2010-06-08

  https://doi.org/10.4084/mjhid.2010.015

  1081

  PDF: 692

  HTML: 2267

• Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity

  Eleftheria Lamprianidou, Chryssoula Kordella, Menelaos Papoutselis, Zoi Bezyrgiannidou, Evangelia Nakou, Spyros Papamichos, Emmanouil Spanoudakis, Andreas Giannopoulos, Katerina Zoi, Ioannis Kotsianidis

  e2017066

  2017-11-01

  https://doi.org/10.4084/mjhid.2017.066

  2429

  PDF: 856

  HTML: 1304

• HOW I TREAT NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA

  Giuseppe Avvisati

  e2011064

  2011-12-19

  https://doi.org/10.4084/mjhid.2011.064

  13388

  PDF: 1058

  HTML: 7331

• Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a real world setting

  Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà

  e2026013

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.013

  685

  PDF: 579

  Html: 109

• TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE

  Vikram Mathews, Ezhilarasi Chendamarai, Biju George, Auro Viswabandya, Alok Srivastava

  e2011056

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.056

  3823

  PDF: 1034

  HTML: 4634

• RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

  Antonio Cuneo, Robin Foà

  e2019024

  2019-02-27

  https://doi.org/10.4084/mjhid.2019.024

  2870

  PDF: 1759

  HTML: 402

• The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study

  Sanaa Kamal, Moheyeldeen Mohamed Naghib, Jamaan Al Zahrani, Huda Hassan, Karim Abdel Aziz Moawado, Omar Arrahman

  e2021007

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.007

  2654

  PDF: 1025

  HTML: 389

• INFECTIOUS RISKS AND COMPLICATIONS IN ADULT LEUKEMIC PATIENTS RECEIVING BLINATUMOMAB

  Wonhee So, Shuchi Pandya, Rod Quilitz, John Greene

  e2018029

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.029

  3152

  PDF: 1165

  HTML: 387

• BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE

  Michele Malagola

  e2017036

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.036

  4907

  PDF: 925

  HTML: 1121

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1559

  HTML: 268

  PDF: 926

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  4648

  Suppl. Files: 1266

  PDF: 1164

  Html: 322

• QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

  Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods

  e2011057

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.057

  1486

  PDF: 758

  HTML: 1398

  cover letter: 253

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1751

  PDF: 699

  HTML: 2453

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2443

  PDF: 2160

  HTML: 242

• Measurement of erythrocyte lifespan using a CO breath test in patients with thalassemia and the impact of treatment erythrocyte lifespan in patients with thalassemia

  xiaolin yin, Jingting Luo

  e2023050

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.050

  910

  PDF: 632

  HTML: 218

• CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENT

  Athanasios Aessopos, Vasilios Berdoukas

  e2009002

  2009-07-18

  1760

  PDF: 522

  HTML: 1584

• KINETICS AND ROLE OF PANCREATIC STONE PROTEIN AND MIDREGIONAL PROADRENOMEDULLIN AS PREDICTORS OF SEPSIS AND BACTEREMIA IN CHILDREN WITH HAEMATOLOGICAL MALIGNANCIES.

  Vasiliki Antari, Lemonia Skoura, Athanasios Tragiannidis, Emmanuel Hatzipantelis, Vasiliki-Rengina Tsinopoulou, Konstantina Papakonstantinou, Efthimia Protonotariou, Assimina Galli-Tsinopoulou

  e2023065

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.065

  1077

  PDF: 823

  HTML: 256

• ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

  Alessandro Busca, Livio Pagano

  e2016039

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.039

  4955

  PDF: 1634

  HTML: 2278

  Untitled: 278

  Untitled: 298

  Untitled: 315

  Untitled: 268

  Untitled: 279

• BETA THALASSEMIA MAJOR IN A DEVELOPING COUNTRY: EPIDEMIOLOGICAL, CLINICAL AND EVOLUTIONARY ASPECT

  Mohamed Bejaoui, Naouel Guirat

  e2013002

  2013-01-01

  https://doi.org/10.4084/mjhid.2013.002

  1766

  PDF: 960

  HTML: 2546

• OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

  Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien

  e2015003

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.003

  2422

  PDF: 1128

  HTML: 2033

  Characteristic of study group: 249

• CURING HEMOGLOBINOPATHIES: CHALLENGES AND ADVANCES OF CONVENTIONAL AND NEW GENE THERAPY APPROACHES.

  Irene Motta, Valentina Ghiaccio, Andrea Cosentino, Laura Breda

  e2019067

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.067

  3183

  PDF: 1942

  HTML: 945